Meghmani Organics' six-year audit record is unqualified, but the FY2026 report carries an Emphasis of Matter on an unimpaired loss-making subsidiary, and the parent's reported profit leans heavily on other income. Three things deserve attention: Kilburn Chemicals' losses and covenant breaches sit unimpaired pending an NCLT amalgamation, quarterly bank statements did not agree with the books in two separate years, and parent-guaranteed subsidiary borrowings of ₹200 crore for Kilburn Chemicals and ₹106 crore for Meghmani Crop Nutrition sit off the parent's reported debt.
Key findings
- Kilburn Chemicals' losses and net-worth erosion remain unimpaired
Major- The investment in wholly owned subsidiary Kilburn Chemicals Limited has not been impaired despite substantial losses and significant net-worth erosion as at 31 March 2026, with management deferring any write-down pending NCLT approval of a Scheme of Amalgamation with an appointed date of 1 January 2026. The FY2026 standalone auditor's report carries an Emphasis of Matter, a special call-out in the audit report, on this non-impairment; the opinion was not modified. Kilburn reported PAT losses of ₹(4,256.02) lakhs in FY2023-24 and ₹(8,907.93) lakhs in FY2024-25, and its retained earnings deficit deepened from ₹(16,462.10) lakhs at 31 March 2025 to ₹(24,336.89) lakhs at 31 December 2025. - Quarterly bank statements did not agree with the books in two years
Major- The FY2026 CARO clause 2(b) states that quarterly statements of current assets filed with banks for working capital limits exceeding ₹5 crore were not in agreement with the books of account. The FY2022 CARO clause (ii)(b) recorded the same disagreement, and the FY2022 AGM outcome noted this as the only qualification in the auditors' report. The audit-trail exception, where the edit log was not enabled for certain privileged access changes to the SAP application and underlying HANA database, appears in the standalone and consolidated auditor's reports for FY2024, FY2025 and FY2026, with no instance of tampering found in any year. - Parent-guaranteed subsidiary debt sits off the parent's books
Major- Meghmani Organics gave a corporate guarantee of ₹200 crore on behalf of Kilburn Chemicals Limited as at 31 March 2026, down from ₹325 crore as at 31 March 2025. A further corporate guarantee of ₹106 crore stood on behalf of Meghmani Crop Nutrition Limited as at 31 March 2026, down from ₹256 crore as at 31 March 2025. Kilburn's Rupee Term Loan of ₹250 crore, secured and corporate guaranteed by Meghmani Organics, had ₹143.9 crore outstanding as at 31 March 2026, while Meghmani Crop Nutrition's ₹56 crore facility had ₹43.86 crore outstanding. - Other income of ₹92 crore was 87.6% of profit before tax
Major- Other income of ₹92 crore constituted 87.6% of profit before tax of ₹105 crore in the latest period. Consolidated PAT was ₹64 crore versus standalone PAT of ₹142 crore in the latest period, meaning 122% of standalone profit sat at subsidiaries. The Company recognised fair value gains of ₹11.24 crore in FY2021 and ₹9.46 crore in FY2022 on OCRPS of Meghmani Finechem Limited transferred under the Scheme. - Related-party dealings are dominated by promoter-controlled Epigral
Major- For FY2021-22, Meghmani Organics reported a material related-party transaction with Meghmani Finechem Limited, now Epigral Limited, aggregating ₹184.95 crore, equivalent to 11.30% of consolidated turnover, ratified by shareholders at the FY2022 AGM. For FY2022-23, shareholders approved an omnibus resolution for material related-party transactions with Meghmani Finechem Limited up to ₹450 crore plus dividend on redeemable preference shares of ₹15.39 crore. All Non-Independent Directors of Meghmani Organics together with their relatives held 71.49% shares in Epigral Limited as disclosed in the FY2023-24 AGM notice. - Operating cash flow has repeatedly failed to cover dividends
Major- Consolidated CFO/PAT was 0.21x in FY22, 0.86x in FY23, -2.35x in FY24, -6.25x in FY25, and 7.72x in FY26. The Board recommended a final dividend of ₹1.40 per share for FY2020-21, FY2021-22, and FY2022-23, each with a payout of ₹35.6 crore, despite consolidated CFO of ₹64.83 crore in FY22 and ₹204 crore in FY23. The Agro V Multi-purpose plant project started in FY2021-22 with an estimated budget of ₹450 crore; Phase I was capitalised in Q4 FY2022-23, Phase II in Q2 FY2024-25, and Phase III capitalisation was slowed due to the current market scenario with expected completion in FY2026-27. - Statutory auditor changed from S R B C & Co to Mukesh M. Shah & Co
Major- S R B C & Co LLP was appointed as statutory auditor on 4 August 2020 for five consecutive years. The Board on 10 May 2025 appointed M/s. Mukesh M. Shah & Co as statutory auditors for five years, and shareholders approved the appointment at the 6th AGM held on 28 June 2025 with 11,49,57,225 votes in favour and 270 votes against. Statutory auditor fees fell to ₹20.00 lakhs in FY2025-26 from ₹36.31 lakhs in FY2024-25. - Public institutions voted near-unanimously against promoter-backed appointments
Minor- In the September 21, 2023 postal ballot, public institutions voted 97.3576% against the appointments of Mr. Ankit Patel as Chairman & Managing Director, Mr. Karana Patel as Executive Director, and Mr. Darshan Patel as Executive Director, while the promoter group voted 100% in favour of all three. In the April 17, 2026 postal ballot, public institutions voted 98.4785% against the re-appointments of Mr. Manubhai Patel and Ms. Urvashi Shah as Independent Directors, while the promoter group voted 100% in favour of both. On 14 August 2023, five new directors were appointed; Mr. Ankit Patel, Mr. Karana Patel, Mr. Darshan Patel, and Mr. Maulik Patel are cousin brothers.
What to watch
- NCLT sanction of the amalgamation scheme. The Scheme of Amalgamation of Kilburn Chemicals Limited and Meghmani Crop Nutrition Limited with Meghmani Organics Limited follows the 6 June 2026 NCLT-convened meetings.
- Shareholder approval of the amalgamation. The AGM notice dated 14 August 2026 seeks approval for the Scheme of Amalgamation.
- Resolution of the FY2026 CARO clause 2(b) disagreement. The quarterly current-asset statements filed with banks did not agree with the books of account, as reported in the FY2025-26 Annual Report.
- Next CRISIL rating action. The outlook on the ₹1,094 crore bank facilities was revised to Negative on 28 April 2026.
- Phase III of the Agro V MPP project. Completion is expected in FY2026-27 per the FY2025-26 Annual Report.
Bottom line: This is a disclosed and audited record with six years of unqualified opinions, but the risk sits in three places: an unimpaired loss-making subsidiary awaiting an NCLT amalgamation, bank statements that did not agree with the books in two separate years, and parent-guaranteed subsidiary debt that sits off the parent's reported borrowings. The profit quality is thin, with other income carrying most of the pre-tax result. Watch the amalgamation sanction, the CARO clause 2(b) resolution, and the next CRISIL rating action.